Skip to main content
Erschienen in: Supportive Care in Cancer 11/2019

21.02.2019 | Original Article

PROMs following breast-conserving therapy for breast cancer: results from a prospective longitudinal monocentric study

verfasst von: I. Kindts, A. Laenen, M. van den Akker, C. Weltens

Erschienen in: Supportive Care in Cancer | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Treatment of breast cancer includes many options and shared decision making is becoming standard practice. Within the context of treatment individualization, the omission of radiotherapy (RT) can be considered. It is thereby of great importance to correctly foresee the side effects attributed to RT. Data from longitudinal studies with contemporary techniques however are sparse. The purpose of the present study was to evaluate patient-reported outcome measures (PROMs) and long-term aesthetic outcome (AO) related to RT in the breast-conserving therapy (BCT) setting for breast cancer over time.

Methods

Patients treated with BCT between April 2015 and April 2016 were prospectively included in the cohort. Evaluations were made at six time points: at baseline (before RT), during and at the end of RT, between 3 and 6 months, 1 year and 2 years after RT. AO was scored by the patient and by the BCCT.core software. Further PROMs were measured with the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire QLQ-C30/-BR23 and the Body Image after Breast Cancer Questionnaire BIBCQ. Patients were evaluated over 2 years. First, we assessed the evolution in time. Second, we tested the differences in mean scale scores of the PROMs between patients with a favourable and an unfavourable AO.

Results

One hundred seventy-five patients were included in the analysis. At baseline, unsatisfactory levels were already present for several scales. Most unsatisfactory PROMs improved up to 1 year after RT. Complaints of fatigue increased at the start but decreased up to a lower level than that at baseline up to 1 year after RT (mean difference (MD) 7.6, − 12.3, respectively). Cognitive functioning showed a small decrease at the start with no further significant decrease (MD − 4.73, − 0.21, respectively). Breast symptoms significantly increased during RT but decreased afterwards up to 2 years after RT to lower values than those at baseline and were then considered satisfactory (MD 15.6, − 19.7, − 4.1, respectively). AO scored as PROM associated with BCCT.core and with the body image measures.

Conclusions

The study suggests that quality of life and body image are temporarily impaired due to RT. Around one third of patients score their long-term AO as unfavourable. These results should be discussed with the patient and could help in the decision making of the treatment plan and in the clarification of the patient’s expectations.
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Ervik M et al (2014) GLOBOCAN 2012 v1.1, Cancer Incidence and. International Agency for Research on Cancer, Lyon [Cited: March 25, 2018]. http://globocan.iarc.fr Ferlay J, Soerjomataram I, Ervik M et al (2014) GLOBOCAN 2012 v1.1, Cancer Incidence and. International Agency for Research on Cancer, Lyon [Cited: March 25, 2018]. http://​globocan.​iarc.​fr
2.
Zurück zum Zitat Desantis C, Ma J, Bryan L, Jemal A (2014) Breast cancer statistics. CA Cancer J Clinv 6:52–62 Desantis C, Ma J, Bryan L, Jemal A (2014) Breast cancer statistics. CA Cancer J Clinv 6:52–62
3.
Zurück zum Zitat van Maaren M, de Munck L, de Bock G et al (2016) 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol 17:1158–1170PubMed van Maaren M, de Munck L, de Bock G et al (2016) 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol 17:1158–1170PubMed
4.
Zurück zum Zitat Agarwal S, Pappas L, Neumayer L, Kokeny K, Agarwal J (2014) Effect of breast conservation therapy vs mastectomy on disease-specific survival for early-stage breast cancer. JAMA Surg 149:267–274PubMed Agarwal S, Pappas L, Neumayer L, Kokeny K, Agarwal J (2014) Effect of breast conservation therapy vs mastectomy on disease-specific survival for early-stage breast cancer. JAMA Surg 149:267–274PubMed
5.
Zurück zum Zitat Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233–1241PubMed Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233–1241PubMed
6.
Zurück zum Zitat Litière S, Werutsky G, Fentiman IS, Rutgers E, Christiaens MR, van Limbergen E, Baaijens MHA, Bogaerts J, Bartelink H (2012) Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol 13:412–419PubMed Litière S, Werutsky G, Fentiman IS, Rutgers E, Christiaens MR, van Limbergen E, Baaijens MHA, Bogaerts J, Bartelink H (2012) Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol 13:412–419PubMed
7.
Zurück zum Zitat Darby S, McGale P, Correa C et al (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378:1707–1716PubMed Darby S, McGale P, Correa C et al (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378:1707–1716PubMed
8.
Zurück zum Zitat Prescott R, Kunkler I, Williams L et al (2007) A randomised controlled trial of postoperative radiotherapy following breast-conserving surgery in a minimum-risk older population. The PRIME trial. Health Technol Assess 11:141–149 Prescott R, Kunkler I, Williams L et al (2007) A randomised controlled trial of postoperative radiotherapy following breast-conserving surgery in a minimum-risk older population. The PRIME trial. Health Technol Assess 11:141–149
9.
Zurück zum Zitat Darby SC, Ewertz M, McGale P et al (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:387–398 Darby SC, Ewertz M, McGale P et al (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:387–398
10.
Zurück zum Zitat Taylor C, Correa C, Duane F et al (2017) (EBCTCG). Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol 35:1641–1649PubMedPubMedCentral Taylor C, Correa C, Duane F et al (2017) (EBCTCG). Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol 35:1641–1649PubMedPubMedCentral
11.
Zurück zum Zitat Ewertz M, Jensen A (2011) Late effects of breast cancer treatment and potentials for rehabilitation. Acta Oncol 50:187–193PubMed Ewertz M, Jensen A (2011) Late effects of breast cancer treatment and potentials for rehabilitation. Acta Oncol 50:187–193PubMed
12.
Zurück zum Zitat United Kingdom Department of Health (2007) Guidance on the routine colletion of patient reported outcome measures (PROMs) United Kingdom Department of Health (2007) Guidance on the routine colletion of patient reported outcome measures (PROMs)
13.
Zurück zum Zitat Friese C, Harrison J, Janz N et al (2017) Treatment-associated toxicities reported by patients with early-stage invasive breast cancer. Cancer 123:1925–1934PubMedPubMedCentral Friese C, Harrison J, Janz N et al (2017) Treatment-associated toxicities reported by patients with early-stage invasive breast cancer. Cancer 123:1925–1934PubMedPubMedCentral
14.
Zurück zum Zitat Mukesh MB, Qian W, Weilkinson JS et al (2014) Patient reported outcome measures (PROMs) following forward planned field-in field IMRT: results from the Cambridge breast IMRT trial. Radiother Oncol 111:270–275PubMed Mukesh MB, Qian W, Weilkinson JS et al (2014) Patient reported outcome measures (PROMs) following forward planned field-in field IMRT: results from the Cambridge breast IMRT trial. Radiother Oncol 111:270–275PubMed
15.
Zurück zum Zitat Al-Ghazal S, Fallowfield L, Blamey R (1999) Does cosmetic outcome from treatment of primary breast cancer influence psychosocial morbidity? Eur J Surg Oncol 25:571–573PubMed Al-Ghazal S, Fallowfield L, Blamey R (1999) Does cosmetic outcome from treatment of primary breast cancer influence psychosocial morbidity? Eur J Surg Oncol 25:571–573PubMed
16.
Zurück zum Zitat Mukesh M, Qian W, Hak C et al (2016) The Cambridge breast intensity-modulated radiotherapy trial: comparison of clinican- versus patient-reported outcomes. Clin Oncol 28:354–364 Mukesh M, Qian W, Hak C et al (2016) The Cambridge breast intensity-modulated radiotherapy trial: comparison of clinican- versus patient-reported outcomes. Clin Oncol 28:354–364
17.
Zurück zum Zitat Ganz P, Kwan L, Snanton A et al (2004) Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. J Natl Cancer Inst 96:376–387PubMed Ganz P, Kwan L, Snanton A et al (2004) Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. J Natl Cancer Inst 96:376–387PubMed
18.
19.
Zurück zum Zitat Verhoeven K, Kindts I, Laenen A, Peeters S, Janssen H, van Limbergen E, Weltens C (2015) A comparison of three different radiotherapy boost techniques after breast conserving therapy for breast cancer. Breast 24:391–396PubMed Verhoeven K, Kindts I, Laenen A, Peeters S, Janssen H, van Limbergen E, Weltens C (2015) A comparison of three different radiotherapy boost techniques after breast conserving therapy for breast cancer. Breast 24:391–396PubMed
20.
Zurück zum Zitat Chen C, Cano S, Klassen A et al (2010) Measuring quality of life in oncologic breast surgery: a systematic review of patient-reported outcome measures. Breast J 16:587–597PubMed Chen C, Cano S, Klassen A et al (2010) Measuring quality of life in oncologic breast surgery: a systematic review of patient-reported outcome measures. Breast J 16:587–597PubMed
21.
Zurück zum Zitat Ong W, Schouwenburg M, van Bommel A et al (2017) A standard set of value-based patient-centered outcomes for breast cancer. The International Consortium for Health Outcomes Measurement (ICHOM) initiative. JAMA Oncol 3:677–685PubMed Ong W, Schouwenburg M, van Bommel A et al (2017) A standard set of value-based patient-centered outcomes for breast cancer. The International Consortium for Health Outcomes Measurement (ICHOM) initiative. JAMA Oncol 3:677–685PubMed
22.
Zurück zum Zitat Kanatas A, Velikova G, Roe B, Horgan K, Ghazali N, Shaw RJ, Rogers SN (2012) Patient-reported outcomes in breast oncology: a review of validated outcome instruments. Tumori 98:678–688PubMed Kanatas A, Velikova G, Roe B, Horgan K, Ghazali N, Shaw RJ, Rogers SN (2012) Patient-reported outcomes in breast oncology: a review of validated outcome instruments. Tumori 98:678–688PubMed
23.
Zurück zum Zitat Aaronson N, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMed Aaronson N, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMed
24.
Zurück zum Zitat Cocks K, King M, Velikova G et al (2012) Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer 48:1713–1721PubMed Cocks K, King M, Velikova G et al (2012) Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer 48:1713–1721PubMed
25.
Zurück zum Zitat Sprangers M, Groenvold M, Arraras J et al (1996) The European Organization for Research and Treatment of Cancer breast cancer-specific quality of life questionnaire module: first results from a three-country field study. J Clin Oncol 14:2756–2768PubMed Sprangers M, Groenvold M, Arraras J et al (1996) The European Organization for Research and Treatment of Cancer breast cancer-specific quality of life questionnaire module: first results from a three-country field study. J Clin Oncol 14:2756–2768PubMed
26.
Zurück zum Zitat Osaba D, Rodrigues G, Pymes J et al (1998) Interpreting the significance of changes in health-related quality of-life scores. J Clin Oncol 16:139–144 Osaba D, Rodrigues G, Pymes J et al (1998) Interpreting the significance of changes in health-related quality of-life scores. J Clin Oncol 16:139–144
27.
Zurück zum Zitat Baxter NN, Goodwin PJ, Mcleod RS, Dion R, Devins G, Bombardier C (2006) Reliability and validity of the body image after breast cancer questionnaire. Breast J 12:221–232PubMed Baxter NN, Goodwin PJ, Mcleod RS, Dion R, Devins G, Bombardier C (2006) Reliability and validity of the body image after breast cancer questionnaire. Breast J 12:221–232PubMed
28.
Zurück zum Zitat Harris J, Levene M, Svensson G, Hellman S (1979) Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast. Int J Radiat Oncol Biol Phys 5:257–261PubMed Harris J, Levene M, Svensson G, Hellman S (1979) Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast. Int J Radiat Oncol Biol Phys 5:257–261PubMed
29.
Zurück zum Zitat Cardoso JS, Cardoso MJ (2007) Towards an intelligent medical system for the aesthetic evaluation of breast cancer conservative treatment. Artif Intell Med 40:115–126PubMed Cardoso JS, Cardoso MJ (2007) Towards an intelligent medical system for the aesthetic evaluation of breast cancer conservative treatment. Artif Intell Med 40:115–126PubMed
30.
Zurück zum Zitat Bantema-Joppe A, de Bock G, Woltman-van Iersel M et al (2015) The impact of age on changes in quality of life among breast cancer survivors treated with breast-conserving surgery and radiotherapy. Br J Cancer 112:636–643PubMedPubMedCentral Bantema-Joppe A, de Bock G, Woltman-van Iersel M et al (2015) The impact of age on changes in quality of life among breast cancer survivors treated with breast-conserving surgery and radiotherapy. Br J Cancer 112:636–643PubMedPubMedCentral
31.
Zurück zum Zitat Wöckel A, Schwentner L, Krockenberger M, Kreienberg R, Janni W, Wischnewsky M, Thorsten K, Felix F, Riccardo F, Blettner M, Singer S (2017) Predictors of the course of quality of life during therapy in women with primary breast cancer. Qual Life Res 26:2201–2208PubMed Wöckel A, Schwentner L, Krockenberger M, Kreienberg R, Janni W, Wischnewsky M, Thorsten K, Felix F, Riccardo F, Blettner M, Singer S (2017) Predictors of the course of quality of life during therapy in women with primary breast cancer. Qual Life Res 26:2201–2208PubMed
32.
Zurück zum Zitat Budischewski K, Fischbeck S, Mose S (2008) Quality of life of breast cancer patients in the course of adjuvant radiotherapy. Support Care Cancer 16:299–304PubMed Budischewski K, Fischbeck S, Mose S (2008) Quality of life of breast cancer patients in the course of adjuvant radiotherapy. Support Care Cancer 16:299–304PubMed
33.
Zurück zum Zitat Noal S, Levy C, Hardouin A, Rieux C, Heutte N, Ségura C, Collet F, Allouache D, Switsers O, Delcambre C, Delozier T, Henry-Amar M, Joly F (2011) One-year longitudinal study of fatigue, cognitive functions, and quality of life after adjuvant radiotherapy for breast cancer. Int J Radiat Oncol Biol Phys 81:795–803PubMed Noal S, Levy C, Hardouin A, Rieux C, Heutte N, Ségura C, Collet F, Allouache D, Switsers O, Delcambre C, Delozier T, Henry-Amar M, Joly F (2011) One-year longitudinal study of fatigue, cognitive functions, and quality of life after adjuvant radiotherapy for breast cancer. Int J Radiat Oncol Biol Phys 81:795–803PubMed
34.
Zurück zum Zitat Lee T, Kilbreast S, Refshauge K, Pendlebury S, Beith J, Lee M (2008) Quality of life of women treated with radiotherapy for breast cancer. Support Care Cancer 16:399–405PubMed Lee T, Kilbreast S, Refshauge K, Pendlebury S, Beith J, Lee M (2008) Quality of life of women treated with radiotherapy for breast cancer. Support Care Cancer 16:399–405PubMed
35.
Zurück zum Zitat Tabrizi F, Alizadeh S (2017) Cancer related fatigue in breast cancer survivors: in correlation to demographic factors. Maedica (Buchar) 12:106–111 Tabrizi F, Alizadeh S (2017) Cancer related fatigue in breast cancer survivors: in correlation to demographic factors. Maedica (Buchar) 12:106–111
36.
Zurück zum Zitat Browall M, Ahlberg K, Karlsson P, Danielson E, Persson L, Gaston-Johansson F (2008) Health-related quality of life during adjuvant treatment for breast cancer among postmenopausal women. Eur J Oncol Nurs 12:180–189PubMed Browall M, Ahlberg K, Karlsson P, Danielson E, Persson L, Gaston-Johansson F (2008) Health-related quality of life during adjuvant treatment for breast cancer among postmenopausal women. Eur J Oncol Nurs 12:180–189PubMed
37.
Zurück zum Zitat Hsu T, Ennis M, Hood N, Graham M, Goodwin P (2013) Quality of life in long-term breast cancer survivors. J Clin Oncol 31:3540–3548PubMed Hsu T, Ennis M, Hood N, Graham M, Goodwin P (2013) Quality of life in long-term breast cancer survivors. J Clin Oncol 31:3540–3548PubMed
38.
Zurück zum Zitat Visser M, Oort F, van Lanschot J et al (2013) The role of recalibration response shift in explaining bodily pain in cancer patients undergoing invasive surgery: an empirical investigation of the Sprangers and Schwartz model. Psychooncol 22:515–522 Visser M, Oort F, van Lanschot J et al (2013) The role of recalibration response shift in explaining bodily pain in cancer patients undergoing invasive surgery: an empirical investigation of the Sprangers and Schwartz model. Psychooncol 22:515–522
39.
Zurück zum Zitat Goldstein D, Bennett B, Webber K et al (2012) Cancer-related fatigue in women with breast cancer: outcomes of a 5-year prospective study. J Clin Oncol 30:1805–1812PubMed Goldstein D, Bennett B, Webber K et al (2012) Cancer-related fatigue in women with breast cancer: outcomes of a 5-year prospective study. J Clin Oncol 30:1805–1812PubMed
40.
Zurück zum Zitat Heil J, Czink E, Golatta M, Schott S, Hof H, Jenetzky E, Blumenstein M, Maleika A, Rauch G, Sohn C (2011) Change of aesthetic and functional outcome over time and their relationship to quality of life after breast conserving therapy. Eur J Surg Oncol 37:116–121PubMed Heil J, Czink E, Golatta M, Schott S, Hof H, Jenetzky E, Blumenstein M, Maleika A, Rauch G, Sohn C (2011) Change of aesthetic and functional outcome over time and their relationship to quality of life after breast conserving therapy. Eur J Surg Oncol 37:116–121PubMed
41.
Zurück zum Zitat Schmitz K, Speck R, Rye S, DiSipio T, Hayes S (2012) Prevalence of breast cancer treatment sequelae over 6 years of follow-iup: the pulling through study. Cancer 118:2217–2225PubMed Schmitz K, Speck R, Rye S, DiSipio T, Hayes S (2012) Prevalence of breast cancer treatment sequelae over 6 years of follow-iup: the pulling through study. Cancer 118:2217–2225PubMed
42.
Zurück zum Zitat Rayan G, Dawson L, Bezjak A et al (2003) Prospective comparison of breast pain in patients participating in a randomized trial of breast-conserving surgery and tamoxifen with or without radiotherapy. Int J Radiat Oncol Biol Phys 55:154–161PubMed Rayan G, Dawson L, Bezjak A et al (2003) Prospective comparison of breast pain in patients participating in a randomized trial of breast-conserving surgery and tamoxifen with or without radiotherapy. Int J Radiat Oncol Biol Phys 55:154–161PubMed
43.
Zurück zum Zitat Sneeuw K, Aaronson N, Yarnold J et al (1992) Cosmetic and functional outcomes of breast conserving treatment for early stage breast cancer. 2. Relationship with psychosocial functioning. Radiother Oncol 25:160–166PubMed Sneeuw K, Aaronson N, Yarnold J et al (1992) Cosmetic and functional outcomes of breast conserving treatment for early stage breast cancer. 2. Relationship with psychosocial functioning. Radiother Oncol 25:160–166PubMed
44.
Zurück zum Zitat Waljee J, Hu E, Ubel P, Smith D, Newman L, Alderman A (2008) Effect of esthetic outcome after breast-conserving surgery on psychosocial functionaning and quality of life. J Clin Oncol 26:3331–3337PubMed Waljee J, Hu E, Ubel P, Smith D, Newman L, Alderman A (2008) Effect of esthetic outcome after breast-conserving surgery on psychosocial functionaning and quality of life. J Clin Oncol 26:3331–3337PubMed
Metadaten
Titel
PROMs following breast-conserving therapy for breast cancer: results from a prospective longitudinal monocentric study
verfasst von
I. Kindts
A. Laenen
M. van den Akker
C. Weltens
Publikationsdatum
21.02.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 11/2019
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-019-04698-0

Weitere Artikel der Ausgabe 11/2019

Supportive Care in Cancer 11/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.